NavaDerm Secures Up To $30M in Debt Financing from CRG
Summary
They understand provider businesses and I look forward to working with CRG and BelHealth to continue on our path toward building a world class dermatology platform in the Northeast. "This financing provides us the flexibility to aggressively pursue additional growth initiatives and develop our ancillary business lines in skincare products, research, clinical trials with pharmaceutical companies and opening two pathology labs." The firm seeks to invest between $20 to $300 million in companies across the healthcare spectrum, including medical devices, biopharmaceuticals, tools & diagnostics, services and information technology. CRG provides growth capital in the form of long-term debt and equity to support innovative, commercial-stage healthcare companies that address large, unmet medical needs. The firm partners with public and private companies to provide flexible financing solutions and world-class support to achieve exceptional growth objectives with minimal dilution.